ATE220329T1 - Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren - Google Patents

Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren

Info

Publication number
ATE220329T1
ATE220329T1 AT94915822T AT94915822T ATE220329T1 AT E220329 T1 ATE220329 T1 AT E220329T1 AT 94915822 T AT94915822 T AT 94915822T AT 94915822 T AT94915822 T AT 94915822T AT E220329 T1 ATE220329 T1 AT E220329T1
Authority
AT
Austria
Prior art keywords
brain tissue
abnormal brain
capillaries
bradykinin
composition containing
Prior art date
Application number
AT94915822T
Other languages
English (en)
Inventor
Keith L Black
Original Assignee
Keith L Black
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keith L Black filed Critical Keith L Black
Application granted granted Critical
Publication of ATE220329T1 publication Critical patent/ATE220329T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT94915822T 1993-05-10 1994-04-19 Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren ATE220329T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/059,623 US5434137A (en) 1993-05-10 1993-05-10 Method for selective opening of abnormal brain tissue capillaries
PCT/US1994/004269 WO1994027133A1 (en) 1993-05-10 1994-04-19 Method for selective opening of abnormal brain tissue capillaries

Publications (1)

Publication Number Publication Date
ATE220329T1 true ATE220329T1 (de) 2002-07-15

Family

ID=22024161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915822T ATE220329T1 (de) 1993-05-10 1994-04-19 Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren

Country Status (9)

Country Link
US (2) US5434137A (de)
EP (1) EP0698203B1 (de)
JP (1) JPH08509978A (de)
AT (1) ATE220329T1 (de)
AU (1) AU679530B2 (de)
CA (1) CA2162055A1 (de)
DE (1) DE69430951T2 (de)
ES (1) ES2179843T3 (de)
WO (1) WO1994027133A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
AU732043B2 (en) * 1996-11-20 2001-04-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method and composition for enabling passage through the blood-brain barrier
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
AU2002247127A1 (en) * 2001-02-14 2002-08-28 Duke University Therapy for cerebral vasospasm
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
US20050095196A1 (en) * 2003-10-29 2005-05-05 Black Keith L. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
WO2006059252A2 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
EP1836161B1 (de) 2004-12-22 2016-07-20 BHI Limited Partnership Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
DK3851447T3 (da) 2006-10-12 2023-12-04 Bellus Health Inc Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
JP2010526636A (ja) * 2007-05-16 2010-08-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 血液脳関門破壊の評価
EP2342356A4 (de) 2008-09-29 2012-11-21 Univ Ben Gurion Amyloid-beta-peptidasen und verwendungsverfahren dafür
US9147246B2 (en) 2009-08-18 2015-09-29 Ben-Gurion University Of The Negev Research And Development Authority Apparatus and method for analyzing stream of imaging data
WO2013057697A1 (en) 2011-10-19 2013-04-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
JP6526627B2 (ja) 2013-04-24 2019-06-05 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 組織解析用の磁気共鳴マップ
WO2015042119A1 (en) * 2013-09-19 2015-03-26 Burt Tal Systems and methods for intra-target microdosing (itm)
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability

Also Published As

Publication number Publication date
ES2179843T3 (es) 2003-02-01
WO1994027133A1 (en) 1994-11-24
AU679530B2 (en) 1997-07-03
DE69430951T2 (de) 2003-03-27
DE69430951D1 (de) 2002-08-14
EP0698203A1 (de) 1996-02-28
US5434137A (en) 1995-07-18
EP0698203A4 (de) 1997-02-26
JPH08509978A (ja) 1996-10-22
AU6770194A (en) 1994-12-12
EP0698203B1 (de) 2002-07-10
CA2162055A1 (en) 1994-11-24
US5527778A (en) 1996-06-18

Similar Documents

Publication Publication Date Title
ATE220329T1 (de) Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren
TW250435B (de)
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
ATE34077T1 (de) Hautbehandlungsmittel.
ZA9410080B (en) Methods of inhibiting dysfunctional uterine bleeding
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
TR200003144T2 (tr) Tiyenopirimidinler.
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9709466A (es) Medicamento para inhibir el melanoma.
ES8800725A1 (es) Un procedimiento para producir un anticuerpo monoclonal
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
DK0644768T3 (da) Fremgangsmåder og præparater til inhibering af endotelcelle- og fibrinogenfremkaldt inflammation
GR3008320T3 (de)
IT8423800A0 (it) Procedimento di trattamento di stati ipotrofici nel bambino mediante somministrazioni di aspartato di arginina.
Barlow et al. On the conversion of high molecular weight urokinase to the low molecular weight form
EP1616564A3 (de) Beeinflussung von nitrosativem Stress zur Behandlung von Mikroorganismen und Helminthen
RU94024560A (ru) Непептедильные соединения, фармацевтическая композиция на их основе, способ лечения
NO933877D0 (no) Fremgangsmaate for aa forhindre blokkering i katetere
NO914779L (no) Adenosin-forbindelse i ny krystallform, fremgangsmaate fordens fremstilling og terapeutisk anvendelse derav
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
UA28192A (uk) Спосіб оцінки міжклітинних контактів у тканинах пародонта

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties